Kinnate Biopharma Logo
US49705R1059
A2QHVT
KNTE

Kinnate Biopharma

Forecast

The analysts' average price target is €27.34 (+1,029.75%). The median is €27.34 (+1,029.75%).

Buy
  2
Hold
  4
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, Kinnate Biopharma had revenue of €0 and net profit of -€101.9m

(EUR) 2023
YoY
Revenue 0 -
Gross profit -722.78k 28.36%
Net profit -101.9m 4.13%
EBITDA -106.93m 2.73%

Fundamentals

Metric Value
Market capitalization
€113.91m
Number of shares
47.17m
52-week high/low
€6.55 - €0.95
Dividends No
Beta
1.34
P/E ratio
-1.10
PEG ratio
-0.16
P/B ratio
0.77
P/S ratio
0.00

Company profile

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.

Name
Kinnate Biopharma
CEO
Nima Farzan
Headquarters San Francisco, ca
USA
Website
Sector
Materials
Industry
Chemicals
IPO
03/12/2020
Employees 84

Ticker symbols

Exchange Symbol
NASDAQ
KNTE
🍪

Parqet  uses cookies. Learn more